Detalhe da pesquisa
1.
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Nature
; 608(7923): 609-617, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35948633
2.
In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.
EMBO J
; 39(5): e102169, 2020 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31930530
3.
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Nature
; 609(7929): E13, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36050473
4.
Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.
EMBO Mol Med
; 15(12): e17737, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37902007
5.
A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.
Cancer Cell
; 41(5): 986-1002.e9, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37116492
6.
Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.
Nat Commun
; 14(1): 1958, 2023 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37029129
7.
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.
Nat Commun
; 13(1): 6579, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36323660
8.
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
Nat Commun
; 10(1): 397, 2019 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30674894
9.
The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review.
Epigenomics
; 10(5): 673-687, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29692199
10.
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.
Cell Rep
; 23(7): 2107-2118, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29768208